Breaking News
March 22, 2018 - FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
March 22, 2018 - Beer Raises Heart Rate; KardiaBand Hyperkalemia Test; CHD Clinics
March 22, 2018 - A retinal implant that is more effective against blindness
March 22, 2018 - New system based on artificial intelligence provides reliable detection of breast cancer
March 22, 2018 - Research offers new understanding about cause of Parkinson’s disease
March 22, 2018 - HORIBA’s Microsemi CRP analyzer improves quality of care in emergency pediatric units, study shows
March 22, 2018 - Range of Vaginal Dryness Products Can Help Postmenopausal Women: Study
March 22, 2018 - Higher Dose Tx Deemed Safe in Pulmonary TB
March 22, 2018 - Discovery of new ALS gene points to cytoskeleton as potential target for drug development
March 22, 2018 - Diet soda associated with higher odds of diabetic retinopathy
March 22, 2018 - LSD reduces ‘sense of self’
March 22, 2018 - Vitamin D deficiency linked to metabolic syndrome in postmenopausal women
March 22, 2018 - Changes in the intestines may be responsible for reversal of diabetes after bariatric surgery
March 22, 2018 - iPads and Cancer; Clot Retrieval and Stroke: It’s PodMed Double T!
March 22, 2018 - Premature births linked to changes in mother’s bacteria
March 22, 2018 - Brain SPECT scans predict treatment outcomes in patients with depression
March 21, 2018 - Researchers succeed in integrating artificial organelles into cells of living organism
March 21, 2018 - Researchers discover ‘missing mutation’ in severe infant epilepsy
March 21, 2018 - Researchers develop statistics-based computational scheme to zoom in on brain function
March 21, 2018 - Verge joins Genomics England’s Discovery Forum industry partnership
March 21, 2018 - Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
March 21, 2018 - Congenital Cardiac Cath Tx Often Strays from Guidelines
March 21, 2018 - Marked increase in cardiovascular risk factors in women after preeclampsia
March 21, 2018 - New app may help predict, track manic and depressive episodes in bipolar patients
March 21, 2018 - Discovery of genes could lead to development of novel therapies for EBV-related cancers
March 21, 2018 - High-fat, high-cholesterol diet depletes ranks of artery-protecting immune cells
March 21, 2018 - Research misconduct allegations shadow likely CDC appointee
March 21, 2018 - Most Breast Ca Patients Fail to Get Genetic Counseling
March 21, 2018 - Lopsided ear function can lead to lopsided brain development
March 21, 2018 - Acupuncture helps manage menopausal symptoms, review finds
March 21, 2018 - Motor skill training may contribute to reading skills in obese children
March 21, 2018 - Poor dental health may be related to increased diabetes risk
March 21, 2018 - Chronic opioid users at increased risk of complications after spinal fusion surgery
March 21, 2018 - Study uncovers potential therapeutic target against large family of parasites
March 21, 2018 - NSAID use linked to increased risk of atrial fibrillation
March 21, 2018 - Scientists develop brain “stethoscope” that can detect silent seizures
March 21, 2018 - New method predicts effects of global warming on disease
March 21, 2018 - Insurance Company Hurdles Burden Doctors, May Harm Patients
March 21, 2018 - Renal Transplant from HCV-Positive Donors Feasible
March 21, 2018 - Myelodysplastic syndrome: MedlinePlus Medical Encyclopedia
March 21, 2018 - Research reveals brain mechanism involved in language learning
March 21, 2018 - Many parents still hesitate to try early peanut introduction, survey finds
March 21, 2018 - Audiologist urges tinnitus sufferers facing ‘revolving door healthcare’ to seek support
March 21, 2018 - Study reveals impact of prostate cancer on wives and partners of sufferers
March 21, 2018 - ‘Almost a Miracle Drug’: What We Heard This Week
March 21, 2018 - Study shows NIH spent >$100 billion on basic science for new medicines
March 21, 2018 - Columbia researchers identify nerve cells that drive fruit fly’s escape behavior
March 21, 2018 - Sartorius Stedim Biotech selected by ABL Europe to supply single-use process technologies
March 21, 2018 - Increase in coffee consumption may help battle against colon cancer
March 21, 2018 - Hydrogel may accelerate healing of diabetic ulcers
March 21, 2018 - Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
March 21, 2018 - DePuy Synthes introduces ACTIS Total Hip System for improving initial implant stability
March 21, 2018 - ‘Oh, It Was Nothing’
March 21, 2018 - Herbal drug kratom linked to salmonella illnesses, CDC says
March 21, 2018 - New optical point-of-care device could enhance screening for thyroid nodules
March 21, 2018 - FDA Expands Approval of Adcetris (brentuximab vedotin) for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
March 21, 2018 - Eosinophilic Esophagitis: Late Manifestation of Allergic March
March 21, 2018 - Signaling pathway involving the Golgi apparatus identified in cells with Huntington’s disease
March 21, 2018 - Quintupling inhaled steroid doses may not benefit children with asthma
March 21, 2018 - Study shows clear connection between cardiovascular fitness in middle age and dementia risk
March 21, 2018 - Premature babies have higher risks of health complications in Bangladesh
March 21, 2018 - Child’s temperament and parenting influence weight gain in babies
March 21, 2018 - Researchers find the heart to be capable of arrhythmia termination after local gene therapy
March 21, 2018 - Inhealthcare to provide digital infrastructure for NHS to help protect people from falls
March 21, 2018 - Flu Season Finally Slowing Down
March 21, 2018 - Mixed Results for Shorter DAPT in ACS Patients
March 21, 2018 - Scientists discover fish scale-derived collagen effective for healing wounds
March 21, 2018 - Genomics England announces new partnership to improve efficiency of next-generation sequencing analysis
March 21, 2018 - Adjuvant AC chemotherapy found to be effective in treating HRD-positive breast cancer patients
March 21, 2018 - Researchers identify new treatment targets for lung diseases using big data
March 21, 2018 - Kids see more women in science than five decades ago
March 21, 2018 - Research shows link between chronic fatigue syndrome and lower thyroid hormone levels
March 21, 2018 - Alzheimer’s disease on the rise
March 21, 2018 - Two Agents Equal as Pretreatment for Adrenal Tumor Surgery
March 21, 2018 - ‘Icebreaker’ protein opens genome for T cell development, researchers find
March 21, 2018 - Women in medicine shout #Metoo about sexual harassment at work
March 21, 2018 - Mother’s pre-pregnancy waist size may be linked to child’s autism risk
March 21, 2018 - Second hand marijuana smoke can cause serious damage
March 21, 2018 - International study shows benefits of using MRI at the start of prostate cancer diagnosis
March 20, 2018 - Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
New Drugs on Horizon for Atopic Dermatitis

New Drugs on Horizon for Atopic Dermatitis

image_pdfDownload PDFimage_print

The evolution in the understanding of the pathogenesis of atopic dermatitis has fueled drug discovery in this arena.

Both T helper cell type 2 (TH2) lymphocyte-driven inflammation, and inflammatory mediators, have become specific targets for anti-inflammatory therapy, according to Lawrence Eichenfield, MD, a professor of dermatology and pediatrics at the University of California San Diego.

Eichenfield, co-author of a comprehensive article in Clinics in Dermatology on current and emerging topical agents for atopic dermatitis (AD), noted that for early intervention, several small studies have demonstrated that emollients decrease the rate of infants at risk for developing AD. Larger studies are underway, he said.

For established AD, rather than solely focusing on managing flares and treatment of acute disease, “we are starting to emphasize long-term disease control,” Eichenfield said. “Strategies to use topical agents in long-term models have a good evidence basis with either topical corticosteroids, which are generally used two to three times a week, or topical calcineurin inhibitors, which may be used intermittently.”

The goal of such a model is to create topical regimens that will minimize the signs and symptoms of disease, while delivering agents as safely as possible. “This mimics the model for control of asthma, which is not based on simply treating active wheezing, but incorporating a variety of medications to minimize the disease over long periods of time,” Eichenfield said.

In December 2016, crisaborole ointment 2% (Eucrisa) received FDA approval for the treatment of AD, making it “the first new novel agent since 2001,” according to Eichenfield. The phosphodiesterase (PDE)-4 inhibitor agent “is neither a topical corticosteroid nor a topical calcineurin inhibitor. It targets an inflammatory mediator and has been shown to work topically to decrease signs and symptoms of AD.”

Because crisaborole is not a corticosteroid, “there is no atrophy, telangiectasia, or hypopigmentation attributed to the drug’s use,” Eichenfield said.

Crisaborole was approved to treat mild to moderate eczema in pediatric (ages ≥2 years) and adult patients. It works by inhibiting phosphodiesterase 4 (PDE-4).

Eichenfield said he was pleased that crisaborole has been added to his armamentarium of AD therapy, either as monotherapy or along with other topical steroids. “We are using it most commonly in long-term care regimens to minimize patient exposure to topical corticosteroids,” he said.

Furthermore, the absence of limitation of duration of use “is highly valuable.” In his practice, crisaborole has been effective in controlling symptoms in his patients in which no significant adverse effects have been observed, he said.

There are currently other topical PDE-4 agents in development for AD along with agents that target janus kinase inhibitors. “The janus kinase pathway is one that apparently can be very important in mediating the inflammation of AD,” explained Eichenfield.

Currently, there are two approved oral janus inhibitors for non-dermatologic indications: Myelodysplasia and rheumatoid arthritis (RA). One of these inhibitors, tofacitinib (Xeljanz) for RA, “has also been studied for AD [but] that drug is not being actively developed at the present time,” Eichenfield said. “But there are many other janus inhibitors that are in clinical studies for AD.”

Eichenfield said the development of new topical therapies for AD is happening concurrently with the development and early use of both, along with other small molecular agents for systemic therapy.

“It is hoped that the heightened awareness about the disease will bring patients into the dermatologist to allow us to improve their AD and minimize the disease process,” Eichenfield said.

This article originally appeared on our partner’s website Dermatology Times, which is a part of UBM Medica. (Free registration is required.)

Eichenfield disclosed relevant relationships with Anacor (Pfizer), Medimetriks, and Roivant Sciences.


Tagged with:

About author

Related Articles